D'Amico Risk Classification for Prostate Cancer
ورودیهای بالینی بیمار
حداقل ۰.۱ — حداکثر ۵۰۰ • واحد: ng/mL
حداقل ۴۰ — حداکثر ۱۰۰ • واحد: years
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk—
- Intermediate Risk—
- High Risk—
The D'Amico Risk Classification for Prostate Cancer calculates assessing 5-year risk of treatment failure in patients with localized prostate cancer based on clinical factors. Key inputs include psa level. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Assesses 5-year risk of treatment failure in patients with localized prostate cancer based on clinical factors. Stratifies patients into low, intermediate, or high-risk groups to guide treatment decisions and prognosis estimation.
Clinical Indication
The D'Amico Risk Classification for Prostate Cancer is indicated for bedside clinical practice to support Assesses 5-year risk of treatment failure in patients with localized prostate cancer based on clinical factors. Stratifies patients into low, intermediate, or high-risk groups to guide treatment decisions and prognosis estimation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Widely adopted in clinical practice guidelines (NCCN, EAU, AUA).
Risk group determined by highest risk factor among: PSA level (≤10, 10-20, >20 ng/mL), Gleason score (≤6, 7, ≥8), and clinical stage (T1-T2a, T2b, ≥T2c)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| psa_level | float | Yes | Preoperative prostate-specific antigen (PSA) level in ng/mL(ng/mL) |
| gleason_score | integer | Yes | Biopsy Gleason score (sum of primary and secondary patterns) |
| clinical_stage | string | Yes | Clinical tumor (T) stage based on digital rectal examination and imaging |
| patient_age | integer | No | Patient age in years for additional prognostic context(years) |
| treatment_planned | string | No | Planned treatment modality for additional context |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| — | Low Risk | Low risk of treatment failure |
| — | Intermediate Risk | Intermediate risk of treatment failure |
| — | High Risk | High risk of treatment failure |
Evidence-Based References (EBM)
- D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974. doi: 10.1001/jama.280.11.969.DOI: 10.1001/jama.280.11.969
- D'Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 2000;18(6):1164-1172. doi: 10.1200/JCO.2000.18.6.1164.DOI: 10.1200/JCO.2000.18.6.1164
- Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013;64(6):895-902. doi: 10.1016/j.eururo.2013.03.033.DOI: 10.1016/j.eururo.2013.03.033
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2024. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
Related calculators
- Khorana Risk Score for Venous Thromboembolism in Cancer Patients
- IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma
- Gail Model for Breast Cancer Risk
- Fong Clinical Risk Score for Colorectal Cancer Recurrence
- D'Amico Risk Classification for Prostate Cancer